Longin A, Berger-Dutrieux N, Fontaniere B, Cochran A J, Devonec M, Dolbeau D, Guillaud M, Laurent J C
Centre Léon Berard, Lyon, France.
Cancer. 1993 Nov 1;72(9):2651-5. doi: 10.1002/1097-0142(19931101)72:9<2651::aid-cncr2820720921>3.0.co;2-s.
In previous studies, the authors demonstrated the value of the monoclonal antibody (MoAb) BL2-10D1 in identifying malignant transitional cells. In this study, the authors evaluate the possible diagnostic value of a murine MoAb, BL2-10D1, raised against human bladder cancer in the determination of the urothelial origin of metastases in a series of 29 patients with metastatic bladder or prostatic carcinoma.
Using an immunoperoxidase method, BL2-10D1 and anti-prostate-specific antigen (anti-PSA) reactivity were studied, using histologic sections from 18 pelvic lymph nodes and 4 other anatomic sites invaded by transitional cell cancer, and from 7 pelvic lymph nodes containing prostatic cancer.
All lymph nodes containing metastases of transitional cell carcinoma were positive with BL2-10D1, whereas all metastases of prostatic cancer were negative; the four instances of distant urothelial metastases were positive with BL2-10D1 MoAb. Conversely, anti-PSA reacted only with prostatic metastases.
Thus, MoAb BL2-10D1 and anti-PSA complement each other in the separation of cancers of prostatic and urothelial origin, and the BL2-10D1 MoAb has potential usefulness in differentiating between urothelial carcinoma and prostate adenocarcinoma. In patients with bladder tumors of uncertain origin, BL2-10D1 may be helpful in confirming that a tumor is a transitional cell carcinoma.
在先前的研究中，作者证明了单克隆抗体（MoAb）BL2-10D1在识别恶性移行细胞方面的价值。在本研究中，作者评估了一种针对人膀胱癌产生的鼠源单克隆抗体BL2-10D1在确定29例转移性膀胱癌或前列腺癌患者转移灶的尿路上皮起源方面的可能诊断价值。
采用免疫过氧化物酶法，利用18个盆腔淋巴结以及4个其他受移行细胞癌侵犯的解剖部位的组织切片，还有7个含有前列腺癌的盆腔淋巴结组织切片，研究BL2-10D1和抗前列腺特异性抗原（抗PSA）的反应性。
所有含有移行细胞癌转移灶的淋巴结BL2-10D1均呈阳性，而所有前列腺癌转移灶均为阴性；4例远处尿路上皮转移灶BL2-10D1单克隆抗体呈阳性。相反，抗PSA仅与前列腺转移灶反应。
因此，单克隆抗体BL2-10D1和抗PSA在区分前列腺和尿路上皮起源的癌症方面相互补充，并且BL2-10D1单克隆抗体在鉴别尿路上皮癌和前列腺腺癌方面具有潜在用途。在起源不明的膀胱肿瘤患者中，BL2-10D1可能有助于确认肿瘤是否为移行细胞癌。
